EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS

EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS

The aim of this study was to identify the most effective (in the clinical and pharmacoeconomic aspects) drug for the treatment of widespread progressing differentiated thyroid cancer (DTC) refractory to radioactive iodine in patients – residents of the Russian Federation.Materials and Methods. The b...

Full description

Bibliographic Details
Main Authors:	M. Yu. Frolov, V. A. Rogov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2017-05-01
Series:	Фармакоэкономика
Subjects:	lenvatinib sorafenib “cost-effectiveness” analysis budget impact analysis pharmacoeconomics thyroid cancer
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/177

Similar Items

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
by: Anne Christine Kaae, et al.
Published: (2021-11-01)

PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2018-02-01)

Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
by: Nigel Fleeman, et al.
Published: (2020-01-01)

Modern therapy of radioactive iodine-refractory differentiated thyroid cancer: resolution of the Expert Council
by: P O Rumyantsev, et al.
Published: (2016-09-01)

Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
by: Naoki Fukuda, et al.
Published: (2021-05-01)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
by: Urbano Anido Herranz
Published: (2022-10-01)

Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory‐differentiated thyroid cancer
by: Paula Jimenez‐Fonseca
Published: (2022-10-01)

Impact of Age-Related Genetic Differences on the Therapeutic Outcome of Papillary Thyroid Cancer
by: Seok-Mo Kim, et al.
Published: (2020-02-01)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
by: Soo Young Kim, et al.
Published: (2018-10-01)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
by: Yasuko Hyogo, et al.
Published: (2018-11-01)

PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER
by: R. I. Yagudina, et al.
Published: (2015-03-01)

RETRACTED: Opportunities of the method «Budget impact analysis» for performing pharmacoeconomic research
by: V. V. Ryazhenov, et al.
Published: (2022-06-01)

Pharmacoeconomic effectiveness of lenvatinib in patients with differentiated radioiodine-resistant thyroid cancer
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2022-12-01)

Pharmacoeconomic analysis of the use of actovegin in patients with post-stroke cognitive impairment in the health care system of the Russian Federation
by: V. V. Ryazhenov, et al.
Published: (2018-11-01)

Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis
by: Xiaoyu Ji, et al.
Published: (2022-08-01)

The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib
by: Yuanna Ling, et al.
Published: (2023-07-01)

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer
by: Hyeok Jun Yun, et al.
Published: (2022-01-01)

Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model
by: Kensuke Suzuki, et al.
Published: (2022-08-01)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
by: Burgio V, et al.
Published: (2021-12-01)

Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis
by: Youwen Zhu, et al.
Published: (2022-07-01)

Kinase inhibitors in thyroid cancers
by: Vineeth Sukrithan, et al.
Published: (2024-02-01)

Pharmacoeconomic-guided choice of systemic chemotherapy in metastatic colorectal cancer patients
by: M. Yu. Fedyanin, et al.
Published: (2017-09-01)

Pharmacoeconomics analysis of using a fixed combination of budesonide/formoterol in patients with asthma in the health care system of the Russian Federation
by: Sergey K. Zyryanov, et al.
Published: (2022-08-01)

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review
by: Hui-Yao Huang, et al.
Published: (2020-11-01)

Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient
by: S. Morelli, et al.
Published: (2017-07-01)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020-02-01)

Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population
by: Shou-Wu Lee, et al.
Published: (2022-03-01)

A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario
by: Dipasquale A, et al.
Published: (2021-04-01)

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
by: Tiziana Feola, et al.
Published: (2021-07-01)

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities
by: Loredana Lorusso, et al.
Published: (2021-03-01)

PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Comparative pharmacoeconomic analysis of Paclical® and Taxol® in Russian Federation
by: A. E. Cheberda, et al.
Published: (2018-05-01)

Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
by: Shijie Wang, et al.
Published: (2022-11-01)

Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer
by: Yu-Ling Lu, et al.
Published: (2021-07-01)

THE FEATURES OF METHODOLOGY FOR PHARMACOECONOMICS ANALYSIS OF VACCINATION
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)